Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17224496 | 0.85 | CASP1 (0.38) | RORCATMCA1CA2CA9 | |
| SCHEMBL18560992 | 0.74 | KLF10 (0.43) | RORCESR1ESR2BRAF | |
| SCHEMBL25767568 | 0.74 | ESR1 (0.33) | ESR1ESR2BRAF | |
| SCHEMBL5643020 | 0.74 | TAAR1 (0.44) | CA1CA2CA9 | |
| SCHEMBL25586916 | 0.72 | RORC (0.43) | RORCBRAF | |
| SCHEMBL10227953 | 0.71 | SCN10A (0.38) | ESR1BRAF | |
| SCHEMBL19972561 | 0.70 | RORC (0.41) | RORCESR1ESR2CA1CA2 | |
| SCHEMBL25767593 | 0.70 | CNR1 (0.31) | ESR1ESR2 | |
| SCHEMBL5035784 | 0.68 | CYP19A1 (0.54) | — | |
| SCHEMBL6774397 | 0.68 | KDM4E (0.39) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902730-B2 | Compounds and compositions as toll-like receptor 7 agonists | NOVARTIS AG (CH) | 2018-02-27 | — | — | US | disclosed |
| US-20170057968-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057968-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | TLR7, TLR3, TLR1 | RORC 84/4885ATM 1196/4885ESR1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.